NCT06643728Active, not recruitingPhase 2
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 26 May 2026
Brief summary (registry, in English)
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 252 (actual)
- First submitted
- 14 Oct 2024
- Start date
- 21 Oct 2024
- Primary completion date
- 16 Jan 2026
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT06643728
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 252
- From 21 Oct 2024 to the primary completion date, 16 Jan 2026
- 12 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have a prior or planned surgical treatment for obesity
- Have Type 1 Diabetes, latent autoimmune diabetes, been diagnosed with any form of diabetes mellitus except for a prior diagnosis of gestational diabetes mellitus, or history of ketoacidosis or hyperosmolar coma
- Have any of the following cardiovascular conditions within 3 months prior to screening:
- acute myocardial infarction
- cerebrovascular accident (stroke)
- unstable angina, or
- hospitalization due to congestive heart failure
- Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening
Other illness
- Have poorly controlled hypertension
- Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes
- Have ongoing or a history of bradyarrhythmias other than sinus bradycardia
- Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure
- Have a history of symptomatic gallbladder disease within the past 2 years
- Have signs and symptoms of any liver disease
- Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality
- Have a history of acute or chronic pancreatitis
- Have renal impairment, measured as estimated glomerular filtration rate \<30 mL/minute/1.73 m2
Lab values
- Have at least one laboratory value suggestive of diabetes during screening
- Use of metformin, or any other glucose-lowering medications
Who the study is looking for
- Have a BMI of
- ≥30 kilograms per square meter (kg/m2) or
- ≥27 kg/m2 and \<30 kg/m2, with at least one of the following weight-related comorbidities:
- Hypertension
- Dyslipidemia
- Cardiovascular disease
- Obstructive sleep apnea
- Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss)
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pinnacle Research Group, LLC Coordinator of this site? Confirm its status | Anniston | United States | Unknown status |
| Central Research Associates Coordinator of this site? Confirm its status | Birmingham | United States | Unknown status |
| Great Lakes Clinical Trials - Ravenswood Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
| East-West Medical Research Institute Coordinator of this site? Confirm its status | Honolulu | United States | Unknown status |
| Clinical Neuroscience Solutions, Inc. dba CNS Healthcare Coordinator of this site? Confirm its status | Jacksonville | United States | Unknown status |
| Altus Research Coordinator of this site? Confirm its status | Lake Worth | United States | Unknown status |
| Suncoast Research Group Coordinator of this site? Confirm its status | Miami | United States | Unknown status |
| Keystone Clinical Studies Coordinator of this site? Confirm its status | Plymouth Meeting | United States | Unknown status |
| Eastside Research Associates Coordinator of this site? Confirm its status | Redmond | United States | Unknown status |
| Rainier Clinical Research Center Coordinator of this site? Confirm its status | Renton | United States | Unknown status |
| SKY Integrative Medical Center/SKYCRNG Coordinator of this site? Confirm its status | Ridgeland | United States | Unknown status |
| Diablo Clinical Research, Inc. Coordinator of this site? Confirm its status | Walnut Creek | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.